
A)
VEGF
VEGFA fold change normalised to RPLP0
****
****
Normoxia
24hrs
24hrs plus 6hrs reperfusion
Duration of hypoxia
B)
HPRT1
HPRT1 Ct value
****
ns
Normoxia
24hrs
24hrs plus 6hrs reperfusion
Duration of hypoxia
C)
RPLP0
RPLP0 Ct value
ns
Normoxia
24hrs
24hrs plus 6hrs reperfusion
Duration of hypoxia
D)
H2AFX
H2AFX fold-change normalised to RPLP0
ns
*
E)
S1PR1
S1PR1 fold-change normalised to RPLP0
*
*
ns
Transfection
Anti-miR-24
Anti-miR-145
Scramble ASO

*Supplementary Digital Content Figure S1 - A) VEGF is significantly upregulated following 24 hours in our hypoxic chamber (1% oxygen), and returns to normal following a subsequent 6 hours of reoxygenation. B&C) represent changes in Ct values of candidate reference genes following 24 hours of hypoxia and a subsequent 6 hours of reoxygenation. Each displays three biological replicates, and they are representative of three independent experiments. B) Significant changes in the Ct value of HPRT1 (P<0.0001). C) Ct value of RPLP0 does not change significantly (P=0.516). D&E) Transfection with anti-miR-24-3p and anti-miR-145-5p ASO prior to hypoxia and reoxygenation with graphs displaying RT-qPCR fold change in H2AFX and S1PR1 mRNA, normalised to RPLP0. D) Fold change in H2AFX (p=0.016). E) Fold change in S1PR1 (p=0.008). All experiments were performed using HUVECs. ns : non-significant (p>0.05), * : P≤0.05, ** : P≤0.01, **** : P≤0.0001.*



Supplementary Digital Content Figure S2 - Transfection with anti-miR-24-3p and anti-miR-145-5p ASO prior to hypoxia and reoxygenation. A) ASO treatment timeline. B) and C) RT-qPCR fold change in SOD2 and HMOX1 mRNA, normalised to RPLP0, including a normoxia control.